- Home
- PRLD vs XCUR Comparison
PRLD vs XCUR Comparison
Compare PRLD & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- XCUR
- Stock Information
- Founded
- PRLD 2016
- XCUR 2011
- Country
- PRLD United States
- XCUR United States
- Employees
- PRLD N/A
- XCUR N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- XCUR Health Care
- Exchange
- PRLD Nasdaq
- XCUR Nasdaq
- Market Cap
- PRLD 50.1M
- XCUR 59.0M
- IPO Year
- PRLD 2020
- XCUR N/A
- Fundamental
- Price
- PRLD $0.88
- XCUR $7.86
- Analyst Decision
- PRLD Strong Buy
- XCUR
- Analyst Count
- PRLD 2
- XCUR 0
- Target Price
- PRLD $4.50
- XCUR N/A
- AVG Volume (30 Days)
- PRLD 168.1K
- XCUR 5.7K
- Earning Date
- PRLD 08-11-2025
- XCUR 08-12-2025
- Dividend Yield
- PRLD N/A
- XCUR N/A
- EPS Growth
- PRLD N/A
- XCUR N/A
- EPS
- PRLD N/A
- XCUR N/A
- Revenue
- PRLD $7,000,000.00
- XCUR $500,000.00
- Revenue This Year
- PRLD N/A
- XCUR N/A
- Revenue Next Year
- PRLD N/A
- XCUR N/A
- P/E Ratio
- PRLD N/A
- XCUR N/A
- Revenue Growth
- PRLD N/A
- XCUR N/A
- 52 Week Low
- PRLD $0.61
- XCUR $1.44
- 52 Week High
- PRLD $6.80
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- PRLD 48.33
- XCUR 31.28
- Support Level
- PRLD $0.85
- XCUR $7.53
- Resistance Level
- PRLD $1.25
- XCUR $8.96
- Average True Range (ATR)
- PRLD 0.10
- XCUR 0.69
- MACD
- PRLD -0.02
- XCUR -0.20
- Stochastic Oscillator
- PRLD 18.52
- XCUR 6.42
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.